ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: A study in 36 patients

Leukemia and Lymphoma

Volumn 33, Issue 3-4, 1999, Pages 313-319

  Saletti, Piercarlo ^a   Zucca, Emanuele ^a   Gueneau, Melanie ^b   Peccatori, Fedro ^b   Cavalli, Franco ^a   Martinelli, Giovanni ^b  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Advanced Hodgkin's disease; Chemotherapy; ChlVPP; Etoposide; Hybrid regimen

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HODGKIN DISEASE; HUMAN; INFECTION; MALE; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SECOND CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032947935     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058431     Document Type: Article

References (26)

1. Canellos GP (1992) Current therapeutic strategies in Hodgkin's disease. Ann Oncol, 3 (Suppl 4), S67-S68.
2. Longo DO, Young RC, Wesley M, et al. (1986) Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4, 1295-1306.
3. Vose JM, Biermann PJ, Anderson JR, et al. (1991) ChlVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable loxicity. J Clin Oncol, 9, 1421-1425.
4. Swerdlow AJ, Barber JA, Horwich A, et al. (1997) Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer, 75, 116-123.
5. Bonadonna G, Zucchi R, Monfardini S. et al. (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamine versus MOPP. Cancer, 36, 252-259.
6. Santoro A, Bonadonna G, Valagussa P, et al. (1987) Long term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol, 5, 27-37.
7. Goldie JH, Coldman AJ. (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 63, 1727-1733.
8. Klimo P, Connors JM. (1985) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol, 3, 1174-1182.
9. Viviani S, Bonadonna G, Santoro A, et al. (1991) Alternating versus Hybrid MOPP-ABVD in Hodgkin's disease: The Milan experience. Ann Oncol, 2, 55-62.
10. Taylor ME, McElwain TJ, Barret A, et al. (1982) Etoposide as single agent in advanced relapsed lymphomas. A phase II study. Cancer Chemoter Pharmacol, 7, 175-177.
11. Cavalli F. (1985) VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK). Semin Oncol, 12, 33-36.
12. Lukes RJ, Gompel LF, Hall TC, et al. (1966) Report of Nomenclature Committee. Rye Classification. Cancer Res, 26, 1311-1320.
13. Berard CW, Hutchison RE (1997) The problem of classifying lymphomas: An orderly prescription for progress. Ann Oncol, 8 (Suppl 2), S3-S9.
14. Carbone PP, Kaplan HS, Musshoff K, et al. (1971) Report of the committee of Hodgkin's disease staging. Ann Arbor classification. Cancer, 31, 1860-1861.
15. Miller AB, Hoogstraten B, Staquet M, et al. (1981) Reporting results of cancer treatment. Cancer, 47, 65-74.
16. Kaplan EL, Meier P. (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc, 54, 457-481.
17. Peto R, Armitage P, Breslow NR, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer, 35, 1-39.
18. Zar JH. (1984) Biostatistical analysis, pp 378-379. Englewood, NJ: Prentice-Hall.
19. Canellos GP, James MD, Anderson JR, et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 327, 1478-1484.
20. Fuchs R, Loeffler M, Pfreundschuh M, et al. (1994) Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymph, 14, 79-89.
21. Pfreundschuh M, Rueffer U, Lathan B, et al. (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol, 12, 580-586.
22. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. (1991) BNLI randomized study of MOPP against LOPP in advanced Hodgkin's disease- long term results. Br J Cancer, 63, 579-582.
23. Selby P, Patel P, Milan S, et al. (1990) ChlVPP combination chemotherapy for Hodgkin's disease: Long-term results. Br J Cancer, 62, 279-285.
24. Glick JH, Young ML, Harrington D, et al. (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the Intergroup Trial. J Clin Oncol, 16, 9-26.
25. O'Reilly SE, Klimo P, Connors JM, et al. (1991) The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer, 67, 271-280.
26. Kumar L. (1993) Epipodophyllotoxins and secondary leukemia. Lancet, 342, 819-820.